Home›Stock Screener›Shukra Pharmaceuticals›Quarterly Results

Shukra Pharmaceuticals Quarterly Results

Latest Quarter Net Profit
₹-2 Cr
QMar 2026
Quarterly Results

Shukra Pharmaceuticals quarterly results. In Mar 2026, Shukra Pharmaceuticals (SHUKRAPHAR) reported revenue ₹7 Cr and net profit ₹-2 Cr — revenue -53.3% YoY. Check SHUKRAPHAR market value to track the company's total market size over time.

SHUKRAPHAR Quarterly Results — Revenue, Profit & EPS Highlights

Shukra Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit SHUKRAPHAR share price.

  • Revenue of ₹7 Cr in Mar 2026 (-70.8% vs Jun 2026, -53.3% vs Mar 2025)
  • Net Profit of ₹-2 Cr in Mar 2026 (-115.4% vs Jun 2026, -140.0% vs Mar 2025)
  • EBITDA of ₹2 Cr in Mar 2026 (-90.0% vs Jun 2026)
  • Operating Margin of 11.0% in Mar 2026 (-70.0pp vs Jun 2026)
  • Earnings Per Share of ₹-0.04 in Mar 2026 (-113.3% vs Jun 2026)

Shukra Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS

SHUKRAPHAR quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Mar 2026 Jun 2026 Sept 2025 Mar 2025 Jun 2025 QoQ YoY
Revenue (₹ Cr) 7 24 8 15 7 -70.8% -53.3%
Net Profit (₹ Cr) -2 13 2 5 1 - -
EBITDA (₹ Cr) 2 20 1 9 2 - -
EPS (₹) -0.04 0.30 0.05 0.12 0.02 - -
Operating Margin (%) 11.0% 81.0% -7.0% 55.0% 24.0% - -

SHUKRAPHAR Share Price Trend — 1-Year Movement Across Quarterly Results

Shukra Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Review SHUKRAPHAR earnings multiple to evaluate earnings-based valuation against sector peers.

Profitability Ratios

Profit Margin -28.6%
EBITDA Margin 28.6%
Operating Margin 11.0%
ROE (Annual) -8.9%

Balance Sheet Highlights

Total Assets ₹117 Cr
Total Equity ₹90 Cr
Current Assets ₹84 Cr
Current Liabilities ₹5 Cr

Cash Flow Analysis

Operating Cash Flow ₹3 Cr
Investing Cash Flow ₹-14 Cr
Financing Cash Flow ₹5 Cr
Net Cash Flow ₹-6 Cr

Current Market Data

Current Price ₹70.49
Exchange NSE
Last Updated Oct 05, 2026

Revenue Trend (₹ Cr)

Mar 2025 15
Sept 2025 8
Jun 2026 24
Mar 2026 7

Net Profit Trend (₹ Cr)

Mar 2025 5
Sept 2025 2
Jun 2026 13
Mar 2026 -2

Operating Margin Trend (%)

Mar 2025 55.0%
Sept 2025 -7.0%
Jun 2026 81.0%
Mar 2026 11.0%

SHUKRAPHAR vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Shukra Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Mar 2026 		₹432,120.23 Cr 1779.7 15,018 2,710 -5.6% - 18.0% 157.5
Divis Laboratories
Mar 2026 		₹244,124.91 Cr 9196.0 2,986 751 -5.0% - 25.2% 324.8
Torrent Pharmaceuti…
Mar 2026 		₹188,719.51 Cr 4772.0 4,111 364 +27.7% +42.2% 8.9% 414.6
Zydus Life Science
Mar 2026 		₹113,615.69 Cr 1139.0 7,569 1,341 -4.3% - 17.7% 90.0
Cipla
Mar 2026 		₹108,576.18 Cr 1335.5 6,612 543 -9.3% - 8.2% 194.4
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data

QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores